The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
BACKGROUND
Each year, worldwide about 530,000 women die from causes related to pregnancy and childbirth. Of the deaths 99% are in low and middle income countries. Obstetric haemorrhage is the leading cause of maternal mortality, most occurring in the postpartum period. Systemic antifibrinolytic agents are widely used in surgery to prevent clot breakdown (fibrinolysis) in order to reduce surgical blood loss. At present there is little reliable evidence from randomised trials on the effectiveness of tranexamic acid in the treatment of postpartum haemorrhage.


METHODS
The Trial aims to determine the effect of early administration of tranexamic acid on mortality, hysterectomy and other morbidities (surgical interventions, blood transfusion, risk of non-fatal vascular events) in women with clinically diagnosed postpartum haemorrhage. The use of health services and safety, especially thromboembolic effect, on breastfed babies will also be assessed. The trial will be a large, pragmatic, randomised, double blind, placebo controlled trial among 15,000 women with a clinical diagnosis of postpartum haemorrhage. All legally adult women with clinically diagnosed postpartum haemorrhage following vaginal delivery of a baby or caesarean section will potentially be eligible. The fundamental eligibility criterion is the responsible clinician's 'uncertainty' as to whether or not to use an antifibrinolytic agent in a particular woman with postpartum haemorrhage. Treatment will entail a dose of tranexamic acid (1 gram by intravenous injection) or placebo (sodium chloride 0.9%) will be given as soon as possible after randomisation. A second dose may be given if after 30 minutes bleeding continues, or if it stops and restarts within 24 hours after the first dose. The main analyses will be on an 'intention to treat' basis, irrespective of whether the allocated treatment was received or not. Subgroup analyses for the primary outcome will be based on type of delivery; administration or not of prophylactic uterotonics; and on whether the clinical decision to consider trial entry was based primarily on estimated blood loss alone or on haemodynamic instability. A study with 15,000 women will have over 90% power to detect a 25% reduction from 4% to 3% in the primary endpoint of mortality or hysterectomy.
Shakur
Haleema
H
Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK. haleema.shakur@lshtm.ac.uk
Elbourne
Diana
D
Gülmezoglu
Metin
M
Alfirevic
Zarko
Z
Ronsmans
Carine
C
Allen
Elizabeth
E
Roberts
Ian
I
D000328:Adult; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001942:Breast Feeding; D004311:Double-Blind Method; D005260:Female; D006439:Hemodynamics; D006801:Humans; D007044:Hysterectomy; D007275:Injections, Intravenous; D007391:International Cooperation; D015990:Placebo Effect; D006473:Postpartum Hemorrhage / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology / Q000601:surgery; D011247:Pregnancy; D012107:Research Design; D013997:Time Factors; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid
Obstet Gynecol. 1999 Oct;94(4):595-9
10511366
Lancet. 2006 Sep 30;368(9542):1189-200
17011946
Lancet. 2005 Feb 19-25;365(9460):711-22
15721478
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD001886
17943760
Br J Cancer. 1977 Jan;35(1):1-39
831755
Br J Radiol. 1971 Oct;44(526):793-7
4940475
Int J Gynaecol Obstet. 2006 Sep;94(3):243-53
16842791
Lancet. 1993 Oct 9;342(8876):891-4
8105166
J Clin Pathol Suppl (R Coll Pathol). 1980;14:35-40
6159375
Br J Obstet Gynaecol. 1997 Mar;104(3):278-84
9091002
Ann Intern Med. 2005 Nov 15;143(10):697-706
16287790
Drugs. 1999 Jun;57(6):1005-32
10400410
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005 Jul;25(7):658-61
16089150
Obstet Gynecol. 1999 Nov;94(5 Pt 1):730-4
10546719
Mymensingh Med J. 2005 Jan;14(1):95-119
15695967
Womens Health Issues. 2009 Jan-Feb;19(1):14-20
19111783
J Clin Pathol Suppl (R Coll Pathol). 1980;14:55-9
7000848
Semin Thromb Hemost. 2003 Apr;29(2):125-30
12709915
BMC Pregnancy Childbirth. 2009 Jul 15;9:29
19604358
BMJ. 1998 Oct 31;317(7167):1170-1
9794846
Br Med Bull. 2003;67:1-11
14711750
Anesthesiology. 1995 Feb;82(2):383-92
7856897
Lancet. 2006 Apr 1;367(9516):1066-1074
16581405
N Engl J Med. 1996 Jul 11;335(2):108-14
8649471